Against Alzheimer's Dementia: The Advance of Antioxidants

IN BRIEF

• Oxidative stress is implicated in the processes accompanying Alzheimer's disease, but some individuals show molecular signs of resilience despite the presence of plaques and tangles.
• Post-mortem analyses indicate that cognitively intact individuals with Alzheimer's neuropathology (NDAN) exhibit fewer markers of oxidative damage and a more active antioxidant response compared to patients with dementia. [1]
• Factors such as PGC-1α, antioxidant enzymes (e.g., SOD2, catalase), and microRNA regulation are among the biological mechanisms under investigation. [5][6][7]
• Evidence comes from laboratory studies, post-mortem analyses, and reviews: these are useful for therapeutic hypotheses but do not yet prove the clinical efficacy of antioxidant therapies in dementia. [2][3]

Abstract: what does science say?

Recent research shows that oxidative stress — an imbalance between the production of reactive species and antioxidant defense capacity — is involved in processes associated with Alzheimer's, but the relationship with cognitive loss is complex. Some individuals, defined as NDAN (non-demented with Alzheimer’s neuropathology), present brain lesions characteristic of the disease (amyloid plaques, tau tangles) without manifesting dementia: molecular analyses in these cases suggest a more effective activation of antioxidant systems and mitochondrial maintenance mechanisms that could limit functional damage. The data come from post-mortem studies, cellular and experimental models, and reviews that indicate key roles for transcriptional factors such as PGC-1α, for enzymes such as SOD2 and catalase, and for microRNAs that regulate these pathways. The observations support the idea that cellular resilience to oxidative damage contributes to cognitive preservation, but do not establish definitive causal relationships or the effectiveness of antioxidant interventions in clinical populations.

What the Evidence Shows About Antioxidant Response and Cognitive Resilience

Comparative analyses of post-mortem brain tissue have compared individuals with Alzheimer's dementia, controls, and NDAN subjects. A study that measured markers of oxidative damage and the expression of antioxidant factors in the frontal cortex found higher levels of oxidative stress and compromised defenses in the brains of subjects with dementia, while NDAN subjects showed an opposite profile, with less oxidative damage and greater activation of molecular scavenging systems. [1] These results are consistent with recent reviews that place oxidative stress at the center of the molecular mechanisms interconnecting Aβ accumulation, mitochondrial dysfunction, and inflammation. [2]

It is important to note that observations on post-mortem human tissue describe temporal and molecular associations: they show that the presence of certain antioxidant responses is correlated with cognitive preservation, but they do not allow us to state that such responses are the sole or only cause of resilience. For this reason, the conclusions should be interpreted within an epidemiological and mechanistic framework, not as proof of clinical efficacy of antioxidant interventions. [8]

Main biological mechanisms: what pathways support antioxidant defense?

Role of PGC‑1α and mitochondrial biogenesis

PGC‑1α is a transcriptional coactivator that regulates mitochondrial biogenesis and the expression of genes involved in respiration and antioxidant defense. Experimental studies indicate that alterations in PGC‑1α expression are accompanied by defects in mitochondrial function and increased oxidative stress in cellular and animal models; in human Alzheimer's tissue, a reduction in PGC‑1α linked to clinical progression is often observed. [5][7] However, manipulating PGC‑1α in animal models has yielded heterogeneous results: in some cases it was protective, in others it worsened the deposition of pathological proteins, so its precise role remains complex and dependent on the cellular and temporal context.

microRNA, SOD2 and enzymatic defenses

MicroRNAs are post-transcriptional regulators that modulate the expression of key factors in the antioxidant response. In particular, miRNAs such as miR‑485 (and its variants) have been studied as potential regulators of PGC‑1α and other targets involved in the response to oxidative damage. [7][6] Enzymes such as mitochondrial superoxide dismutase (SOD2) and catalase are central components of the reactive species neutralization system: levels and activities of these enzymes are altered in brains affected by dementia, while in NDANs, signs of preservation or functional up-regulation are observed. [1][4]

Brain cells and regional sections

Neurons, astrocytes, and other glial cells respond differently to oxidative stress. Comparative studies on isolated cells and cortical sections indicate that astrocytes can provide metabolic and antioxidant support to neurons, while specific brain regions (e.g., hippocampus vs. prefrontal cortex) show different vulnerability. These differences complicate the global interpretation of the systemic role of oxidative stress in Alzheimer's and suggest that resilience depends on a network of coordinated mechanisms at the cellular and regional level. [2][6]

Therapeutic Implications and Limitations of Antioxidant Therapies

The biological plausibility that reducing oxidative stress improves neuronal health has led to numerous therapeutic attempts with systemic antioxidants or molecules targeting the mitochondria. However, critical reviews and meta-analyses highlight conflicting results in clinical trials: many trials have not shown clinically relevant benefits, while some experimental interventions have demonstrated effects dependent on dose, administration time, and the studied population. [3] Limitations include pharmacokinetics (poor blood-brain barrier penetration), non-selective targets, and the fact that ROS also have physiological signaling roles: indiscriminate lowering may not always be favorable.

Studies on NDAN suggest that instead of an exclusively antioxidant approach, the most promising strategy might aim to modulate mitochondrial biogenesis, transcriptional regulation (e.g., PGC-1α), and post-transcriptional targets like microRNAs, to promote cellular resilience. However, these hypotheses require well-designed clinical studies to clarify efficacy, safety, and intervention windows. [5][6][3]

PRACTICAL SECTION: What it means in practice

For the general public, evidence indicates that there is a relationship between oxidative stress and pathological processes typical of Alzheimer's, but there is not enough evidence for generic antioxidant supplementation to be recommended for the prevention or treatment of dementia. Research suggests that lifestyle factors known to support mitochondrial health and reduce inflammation — such as regular physical activity, a balanced diet rich in fruits, vegetables, and essential nutrients, control of cardio-metabolic factors, and adequate sleep — are consistent with strategies for reducing risk and maintaining long-term cognitive function. [4][2]

Anyone considering changes in the use of antioxidant supplements or medications should consult their doctor or a specialist: drug interactions and effects in people with comorbidities can be relevant. In clinical and research settings, the current approach favors multimodal interventions targeting cellular mechanisms rather than the empirical use of high-dose antioxidants. [3]

KEY POINTS TO REMEMBER

• Oxidative stress is associated with the pathological processes of Alzheimer's, but it is not the sole determining factor.
• NDAN individuals show molecular profiles indicating a more efficient antioxidant response compared to dementia patients. [1]
• PGC‑1α, SOD2, catalase, and specific microRNAs are key elements studied in resilience to oxidative damage. [5][6][7]
• Clinical trials on antioxidants have yielded mixed results; there are no general recommendations based on strong evidence. [3]
• Multidimensional prevention strategies (lifestyle, risk factor control) remain the primary recommendation for cognitive health. [4]

Limitations of the Evidence

The available evidence comes from different types of studies, each with specific limitations. Observational studies and post-mortem analyses show associations and allow for the formulation of hypotheses about mechanisms, but they do not establish definitive causal relationships. Experimental studies in cells and animal models provide mechanistic evidence, but clinical translation is complex due to interspecies differences and the human biological context. [1][5]

Clinical trials with systemic antioxidants often have methodological limitations: sample size, population heterogeneity, variability in doses and formulations, and poor target selectivity. Furthermore, the physiological role of reactive species and the complexity of signaling networks make a simplified approach aimed solely at neutralizing ROS risky. [3]

Editorial Conclusion

Recent research reinforces the idea that the brain's ability to activate effective antioxidant responses is part of a broader picture of neuronal resilience that can mitigate the effects of Alzheimer's neuropathology. Studies such as the one published in The Journal of Neuroscience document molecular differences between subjects with and without dementia despite having similar histopathological signs, guiding the scientific community towards more targeted investigations into transcriptional factors, post-transcriptional regulation, and mitochondrial support. [1][8] However, clinical translation requires caution: currently, there is no solid evidence to recommend universal antioxidant therapies, and the most pragmatic approach remains the promotion of healthy lifestyles and the search for targeted interventions evaluated in rigorous trials.

Editorial Note

This update has been reviewed according to criteria of transparency and scientific rigor. The text is intended to inform and not to replace personalized medical advice. For clinical clarifications, consult healthcare professionals.

SCIENTIFIC RESEARCH

1. Fracassi A, Marcatti M, Zolochevska O, Tabor N, Woltjer R, Moreno S, Taglialatela G. Oxidative Damage and Antioxidant Response in Frontal Cortex of Demented and Nondemented Individuals with Alzheimer's Neuropathology. The Journal of Neuroscience. 2021;41(3):538–554. https://doi.org/10.1523/JNEUROSCI.0295-20.2020
2. Oliveira MF, et al. Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery. Antioxidants. 2021;10(9):1353. https://doi.org/10.3390/antiox10091353
3. Forman HJ, Zhang H, Rinna A. Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. Nature Reviews Drug Discovery. 2021;20:689–709. https://doi.org/10.1038/s41573-021-00233-1
4. Roberts BR, et al. Oxidative Stress in Brain in Amnestic Mild Cognitive Impairment. Antioxidants. 2023;12(2):462. https://doi.org/10.3390/antiox12020462
5. Agostini M, et al. Upregulation of PGC‑1α expression by Alzheimer’s disease-associated pathway: presenilin 1/APP/AICD. Aging Cell. 2014;13:263–272. https://doi.org/10.1111/acel.12183
6. Wang J, et al. PPARγ coactivator-1α (PGC‑1α) protects neuroblastoma cells against amyloid‑β induced cell death and neuroinflammation via NF‑κB pathway. BMC Neuroscience. 2017;18:87. https://doi.org/10.1186/s12868-017-0387-7
7. Correia S, et al. Impaired mitochondrial biogenesis contributes to neuronal dysfunction in Alzheimer disease. Journal of Neurochemistry. 2011; DOI: https://doi.org/10.1111/j.1471-4159.2011.07581.x
8. Kok FK, van Leerdam SL, de Lange ECM, Taglialatela G. Potential Mechanisms Underlying Resistance to Dementia in Non‑Demented Individuals with Alzheimer’s Disease Neuropathology. Journal of Alzheimer’s Disease. 2022;87:51–81. https://doi.org/10.3233/JAD-210607